Literature DB >> 21214912

Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis.

Olivier Facy1, François Radais, Sylvain Ladoire, Delphine Delroeux, Hervé Tixier, François Ghiringhelli, Patrick Rat, Bruno Chauffert, Pablo Ortega-Deballon.   

Abstract

BACKGROUND: The best method to deliver intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis from ovarian cancer is not well defined. The aim of this study was to assess the ability of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a rat model of peritoneal carcinomatosis.
METHODS: Four groups of 5 BDIX rats with ovarian peritoneal carcinomatosis underwent IPC with 30 mg/l of cisplatin according to the following conditions: normothermia at 37° for 1 or 2 hours, hyperthermia at 42°C for 1 hour or normothermia at 37°C for 2 hours with 2 mg/l adrenaline. Tissue platinum content was measured by atomic absorption spectroscopy. The effect of hyperthermia, adrenaline and the duration of exposure to the drug was measured in vivo (tissue concentration of platinum in tumor, abdominal and extra abdominal tissues) and in vitro (cytotoxicity on human ovarian cancer cells).
RESULTS: In vitro, hyperthermia and longer exposure enhanced the accumulation and the cytotoxic effect of cisplatin on cancer cells. In vivo, only the 2 hours treatment with adrenaline resulted in increased platinum concentrations. The rats treated with adrenaline showed significantly lower concentrations of cisplatin in extra peritoneal tissues than those treated with hyperthermia.
CONCLUSION: Adrenaline is more effective than hyperthermia in order to enhance the intratumoral concentration of cisplatin in rats with peritoneal carcinomatosis from ovarian origin. It may also decrease the systemic absorption of the drug.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21214912      PMCID: PMC3024948          DOI: 10.1186/1756-9966-30-4

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  33 in total

1.  A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

2.  Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.

Authors:  Cécile Molucon-Chabrot; Nicolas Isambert; Laurent Benoit; Sylvie Zanetta; Jean Fraisse; Jean-Claude Guilland; Bernard Royer; Pascale Monin-Baroille; Michel Flesch; Pierre Fargeot; Bruno Coudert; Françoise Mayer; Pierre Fumoleau; Bruno Chauffert
Journal:  Anticancer Drugs       Date:  2006-11       Impact factor: 2.248

3.  Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.

Authors:  F Raspagliesi; S Kusamura; J C Campos Torres; G A de Souza; A Ditto; F Zanaboni; R Younan; D Baratti; L Mariani; B Laterza; M Deraco
Journal:  Eur J Surg Oncol       Date:  2006-04-18       Impact factor: 4.424

4.  Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.

Authors:  Shigeki Kusamura; Rami Younan; Dario Baratti; Pasqualina Costanzo; Myriam Favaro; Cecilia Gavazzi; Marcello Deraco
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

5.  Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors.

Authors:  C Duvillard; L Benoit; P Moretto; J L Beltramo; P Brunet-Lecomte; M Correia; C Sergent; B Chauffert
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

Review 6.  Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives.

Authors:  Bruno Chauffert; Patrick Favoulet; Emmanuel Polycarpe; Christian Duvillard; Jean-Luc Beltramo; Francis Bichat; Patrick Rat; Philippe Genne; Laurent Benoit
Journal:  Surg Oncol Clin N Am       Date:  2003-07       Impact factor: 3.495

7.  8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Sjoerd Bruin; Henk Boot; Gooike van Slooten; Harm van Tinteren
Journal:  Ann Surg Oncol       Date:  2008-06-03       Impact factor: 5.344

8.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

9.  Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats.

Authors:  G Los; P Sminia; J Wondergem; P H Mutsaers; J Havemen; D ten Bokkel Huinink; O Smals; D Gonzalez-Gonzalez; J G McVie
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy.

Authors:  Tristan D Yan; Oswald A Stuart; Dal Yoo; Paul H Sugarbaker
Journal:  J Transl Med       Date:  2006-04-10       Impact factor: 5.531

View more
  8 in total

1.  Ovarian carcinomatosis in a dog managed with surgery and intraperitoneal, systemic, and intrapleural chemotherapy utilizing indwelling pleural access ports.

Authors:  Matthew P Best; Angela E Frimberger
Journal:  Can Vet J       Date:  2017-05       Impact factor: 1.008

Review 2.  The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic Review.

Authors:  J Hefner; H Csef
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

3.  Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.

Authors:  Brice Paquette; Elsa Kalbacher; Frédéric Mercier; Zaher Lakkis; Alexandre Doussot; Célia Turco; Edda Caputo; Sébastien Pili-Floury; Bernard Royer; Laura Mansi; Delphine Delroeux; Martin Demarchi; Xavier Pivot; Bruno Chauffert; Elise Clement; Bruno Heyd
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

4.  Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

Authors:  Michelle M Boisen; Scott D Richard; Matthew P Holtzman; Robert P Edwards; Joseph L Kelley; Mohammad Haroon Choudry; David Bartlett; Marilyn Huang
Journal:  J Gastrointest Oncol       Date:  2016-02

5.  Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.

Authors:  B Royer; E Kalbacher; S Onteniente; V Jullien; D Montange; S Piedoux; A Thiery-Vuillemin; D Delroeux; S Pili-Floury; E Guardiola; M Combe; P Muret; V Nerich; B Heyd; B Chauffert; J-P Kantelip; X Pivot
Journal:  Br J Cancer       Date:  2011-12-15       Impact factor: 7.640

6.  Injectable PLGA/Fe3O4 implants carrying cisplatin for synergistic magnetic hyperthermal ablation of rabbit VX2 tumor.

Authors:  Yang Yang; Fengjuan Wang; Kaiyuan Zheng; Liming Deng; Lu Yang; Nan Zhang; Chunyan Xu; Haitao Ran; Zhaoxia Wang; Zhigang Wang; Yuanyi Zheng
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

7.  Alteration of Adaptive Immunity in a Colorectal Peritoneal Carcinomatosis Model.

Authors:  Rongchen Shi; Wei Xiang; Xia Kang; Lili Zhang; Jinping Wang; Hongming Miao; Fengtian He
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

8.  The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model.

Authors:  Min Jeong Jeon; Cheol-Hee Ahn; Hyeonjin Kim; In Jae Chung; Seulhee Jung; Young-Hwa Kim; Hyewon Youn; Jin Wook Chung; Young Il Kim
Journal:  J Exp Clin Cancer Res       Date:  2014-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.